Sensorion seeks partner for inner ear disorder drug

Sensorion CEO Nawal Ouzren speaks to Scrip's Lucie Ellis at the recent BIO-Europe® partnering meeting about the company's two clinical-stage programs that are targeting inner ear conditions. Sensorion is seeking a partner for lead product SENS-111, which will require a large-scale sales force if it successfully reaches the market. Sensorion was founded in 2009 by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and technology platform to develop first-in-class, easy-to-administer, orally active drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.